medigraphic.com

2019, Number 3

<< Back Next >>

Vet Mex 2019; 6 (3)

Anesthetic evaluation of a novel phospholipid-free 1% propofol microemulsion formulation in dogs

Aquino I, Gutiérrez-Blanco E, Ocampo L, Gutiérrez L, Bernad-Bernad MJ, Sumano H

Language: English/Spanish
References: 30
Page: 1-11
PDF size: 132.07 Kb.


ABSTRACT

A novel four-week stable experimental formulation of propofol lacking phospholipids (PMICRO) was assessed as an anesthetic agent in dogs and compared to the customary preparation of propofol that contains phospholipids (PMACRO). Forty healthy mixed-breed dogs were included in this study and randomly assigned (blocking by sex and age), to receive 5 mg/kg of one of these two pharmaceutical propofol preparations, by intravenous injection. Basal and post anesthetic blood biochemical parameters were measured. Also, cardiovascular and respiratory rates were recorded. Onset, duration and recovery from anesthesia, were documented as well. Overall, IV administration of PMICRO induces a short duration anesthesia with rapid recovery in a similar manner to anesthesia achieved with the customary propofol preparation (PMACRO). Because PMICRO lacks phospholipids, it may allow a longer storage time, decreasing the likeliness of accidental administration of contaminated propofol.


REFERENCES

  1. Sumano H, Pérez N, Izquierdo P, Castellanos J. Anestesia general con propofol en perros mediante infusion continua. Experiencias clinicas. Vet México. 1994;25(3):199-205.

  2. Muir W, Gadawski J. Cardiovascular effects of a high dose of romifidine in propofol- anesthetized cats. Am J Vet Res. 2002;63(9):1241-6.

  3. Selmi AL, Figueiredo JP, Mendes GM, Lavor LMS, Machado PML. Infusão contínua de propofol em gatos pré-medicados com cetamina-midazolam. Arq Bras Med Veterinária e Zootec [Internet]. 2005;57(3):295-9 [cited 2016 Nov 27]. Available from: http://www.scielo.br/scielo.php?script=sci_arttext& pid=S0102-09352005000300003&lng=en&nrm=iso&tlng=pt

  4. Sim JY, Lee SH, Park DY, Jung JA, Ki KH, Lee DH, et al. Pain on injection with microemulsion propofol. Br J Clin Pharmacol. 2009;67(3):316-25.

  5. Borwankar RP, Lobo LA, Wasan DT. Emulsion stability - kinetics of flocculation and coalescence. Colloids and Surfaces. 1992;69(2-3):135-46.

  6. Adams H. Veterinary pharmacology and therapeutics. 9th ed. Iowa: Wiley-Blackwell; 2001.

  7. Sumano H, Ocampo L. Manual de farmacología clínica para pequeñas especies. 4th ed. Mexico: Imagen Editorial Yire; 2009.

  8. Ezquerra J, Vives M. Anestesia práctica de pequeños animales. 1st ed. Madrid: McGraw Hill-Interamericana; 1992. 200 p.

  9. Marsico F, Cediel R, Gómez de Segura IA, Tendillo FJ, Criado AB. Un nuevo anestésico intravenoso: propofol : Clínica Vet pequeños Anim [Internet]. 1991;11(4):0231-9. Available from: http://ddd.uab.cat/record/69982

  10. Tsagogiorgas C, Theisinger S, Heesch E, Krebs J, Holm R, Beck G, et al. Evaluation of pharmacokinetic properties and anaesthetic effects of propofol in a new perfluorohexyloctane (F6H8) emulsion in rats. A comparative study. Int J Pharm [Internet]. 2015;486(1-2):69-76. Available from: http://dx.doi.org/10.1016/j. ijpharm.2015.03.037

  11. Thibaut J, Rivera T, Ahumada F. Anestesia endovenosa en perros mediante el uso de propofol en dosis única, premedicado con acepromazina-atropina y xilazina-atropina. Arch Med Vet [Internet]. 2002;34(1):25-35 [cited 2016 Nov 24]. Available from: http://www.scielo.cl/scielo.php?script=sci_arttext& pid=S0301-732X2002000100003&lng=en&nrm=iso&tlng=en

  12. Zorrilla-Vaca A, Escandón-Vargas K, Brand-Giraldo V, León T, Herrera M, Payán A. Bacterial contamination of propofol vials used in operating rooms of a third-level hospital. Am J Infect Control [Internet]. 2016;44(1):e1-3. Available from: http:// dx.doi.org/10.1016/j.ajic.2015.08.009

  13. Cho J, Cho JC, Lee P, Lee M, Oh E. Formulation and evaluation of an alternative triglyceride-free propofol microemulsion. Arch Pharm Res. 2010;33(9):1375-87.

  14. Dubey PK, Kumar A. Pain on injection of lipid-free propofol and propofol emulsion containing medium-chain triglyceride: A comparative study. Anesth Analg. 2005;101(4):1060-2.

  15. Nakane M, Iwama H. A potential mechanism of propofol-induced pain on injection based on studies using nafamostat mesilate. Br J Anaesth. 1999;83(3):397-404.

  16. Allchurch LG V, Crilly H. Fixed drug eruption to propofol. Anaesth Intensive Care. 2014;42(6):777-81.

  17. Graham LF, Torres SMF, Jessen CR, Horne KL, Hendrix PK. Effects of propofol-induced sedation on intradermal test reactions in dogs with atopic dermatitis. Vet Dermatol. 2003;14(3):167-76.

  18. McHale SP, Konieczko K. Anaphylactoid reaction to propofol. Anaesthesia. 1992;47(10):864-5.

  19. Li X, Zhang Y, Fan Y, Zhou Y, Wang X, Fan C, et al. Preparation and evaluation of novel mixed micelles as nanocarriers for intravenous delivery of propofol. Nanoscale Res Lett [Internet]. 2011;6(1):275. Available from: http://www. nanoscalereslett.com/content/6/1/275

  20. Wallentine CB, Shimode N, Egan TD, Pace NL. Propofol in a modified cyclodextrin formulation: First human study of dose-response with emphasis on injection pain. Anesth Analg. 2011;113(4):738-41.

  21. Lang BC, Yang J, Wang Y, Luo Y, Kang Y, Liu J, et al. An improved design of water-soluble propofol prodrugs characterized by rapid onset of action. Anesth Analg. 2014;118(4):745-54.

  22. Minghella E, Benmansour P, Iff I, Senior JM, Mosing M. Pain after injection of a new formulation of propofol in six dogs. Vet Rec [Internet]. 2010;167(22):866- 7. Available from: http://veterinaryrecord.bmj.com/cgi/doi/10.1136/vr.c5736

  23. SAGARPA. Especificaciones técnicas para la producción, cuidado y uso de los animales de laboratorio. [Internet]. Diario oficial de la federación. México; 1999. p. 57. Available from: http://www.senasica.gob.mx/?doc=743

  24. Bayne KAL. Environmental Enrichment of Nonhuman Primates, Dogs and Rabbits Used in Toxicology Studies. Toxicol Pathol. 2004;31(1 Suppl):132-7.

  25. Sumano H, Ocampo L. Farmacología veterinaria. 4th ed. México: Aranda; 2016.

  26. World Health Organization. Stability testing of active pharmaceutical ingredients and finished pharmaceutical products, Annex 10. WHO Expert Comm Specif Pharm Prep. 2018;(52):309-51.

  27. Martinez-Taboada F, Leece EA. Comparison of propofol with ketofol, a propofol- ketamine admixture, for induction of anaesthesia in healthy dogs. Vet Anaesth Analg [Internet]. 2014;41(6):575-82. Available form: http://dx.doi. org/10.1111/vaa.12171

  28. Bigby SE, Beths T, Bauquier S, Carter JE. Postinduction apnoea in dogs premedicated with acepromazine or dexmedetomidine and anaesthetized with alfaxalone or propofol. Vet Anaesth Analg. 2017;44(5):1007-15.

  29. Bjur KA, Cannon BC, Fine AL, Ritter MJ, Schueler KE, Nemergut ME. Propylene Glycol Toxicity in Adolescent with Refractory Myoclonic Status Epilepticus. Case Rep Pediatr [Internet]. 2017;2017:1-3. Available from: https://www.hindawi. com/journals/cripe/2017/2979486/

  30. Nanopolytox. Toxicological impact of nanomaterials derived from processing, weathering and recycling of polymer nanocomposites used in various industrial applications [Internet]. España; 2016. Available from: https://cordis.europa.eu/ project/rcn/94382/brief/es




2020     |     www.medigraphic.com